BioCatalystWatch
ENTAWorkspace / ENTA / OverviewCompany library
ENANTA PHARMACEUTICALS INC logo

ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC (ENTA)

Website

Price
Market cap
Next catalystExpected Q1 2027Zelicapavir — LOTUS · Phase 2 dataSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

EDP-978

KIT

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Zelicapavir

RSV N-Protein

PreINDP1P2FilingApproved
Upcoming / outlook

Zelicapavir

RSV N-Protein

PreINDP1P2P3FilingApproved
Upcoming / outlook

EPS-3903

STAT6

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

EPS-3903

STAT6

PreINDP1P2P3FilingApproved
Upcoming / outlook

EDP-978

KIT

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Zelicapavir

RSV N-Protein

PreINDP1P2P3FilingApproved
Upcoming / outlook

Zelicapavir

RSV N-Protein

PreINDP1P2FilingApproved
Upcoming / outlook

Other pipelines

EDP-978

KIT

PreINDP1P2P3FilingApproved
EPS-5336

MRGPRX2

Upcoming / outlook

EPS-1421

KIT

PreINDP1P2P3FilingApproved
EDP-323

RSV L-protein

PreINDP1P2P3FilingApproved
EDP-323

RSV L-protein

PreINDP1P2P3FilingApproved
EDP-235

3CL protease

PreINDP1P2P3FilingApproved

Partner / License out

Approved / commercial

HCV NS3/4A Protease × HCV NS5A

Approved

PreINDP1P2P3FilingApproved

HCV NS3/4A Protease × HCV NS5A

Approved

PreINDP1P2P3FilingApproved

History / paused

Zelicapavir

RSV N-Protein

PreINDP1P2P3FilingApproved
Zelicapavir

RSV N-Protein

PreINDP1P2P3FilingApproved
Zelicapavir

RSV N-Protein

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ENTA PR & News

PR & News

ENTA SEC archive